Trial Profile
A Phase III, Open-label, Multicenter Trial of Avelumab (MSB0010718C) Versus Platinum-based Doublet as a First-line Treatment of Recurrent or Stage IV PD-L1+NSCLC
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 28 Mar 2024
Price :
$35
*
At a glance
- Drugs Avelumab (Primary) ; Carboplatin; Cisplatin; Gemcitabine; Paclitaxel; Pemetrexed
- Indications Non-small cell lung cancer
- Focus Registrational; Therapeutic Use
- Acronyms JAVELIN Lung 100
- Sponsors EMD Serono; EMD Serono Research & Development Institute; Merck KGaA
- 28 Mar 2024 This study has been completed in Netherland, according to European Clinical Trials Database record.
- 16 Mar 2024 This study has been completed in Portugal, according to European Clinical Trials Database record.
- 19 Feb 2024 Status changed from active, no longer recruiting to completed.